➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKesson
Harvard Business School
Boehringer Ingelheim
Moodys

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,471,067


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,471,067 protect, and when does it expire?

Patent 10,471,067 protects ANJESO and is included in one NDA.

This patent has seventeen patent family members in nine countries.

Summary for Patent: 10,471,067
Title:Nanoparticulate meloxicam formulations
Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.
Inventor(s): Cooper; Eugene R. (Berwyn, PA), Ryde; Tuula (Malvern, PA), Pruitt; John (Suwanee, GA), Kline; Laura (Harleysville, PA)
Assignee: Recro Pharma, Inc. (Malvern, PA)
Application Number:15/437,534
Patent Claim Types:
see list of patent claims
Use; Compound; Dosage form;

Recent additions to Drugs Protected by US Patent 10,471,067

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Baudax ANJESO meloxicam SOLUTION 210583 Feb 20, 2020 RX Yes   Start Trial Y   Start Trial U-2750 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 10,471,067

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes   Start Trial   Start Trial Y MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,471,067

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 431131   Start Trial
Canada 2517679   Start Trial
Germany 602004021107   Start Trial
Denmark 3090731   Start Trial
European Patent Office 1617816   Start Trial
European Patent Office 1938803   Start Trial
European Patent Office 3090731   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
McKesson
Boehringer Ingelheim
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.